封面
市场调查报告书
商品编码
1691755

法布瑞氏症治疗市场 - 全球产业规模、份额、趋势、机会和预测,按药物、按治疗、按给药途径、按配销通路、按地区和竞争进行细分,2020-2030 年预测

Fabry Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs, By Treatment, By Route of Administration, By Distribution Channel, By Region & Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球法布瑞氏症治疗市场价值为 18.6 亿美元,预计在预测期内将出现令人印象深刻的成长,到 2030 年的复合年增长率为 6.30%。法布瑞氏症,也称为安德森-法布瑞氏症,是一种罕见的遗传性疾病,属于一类被称为溶小体贮积症的疾病。这种疾病是由 GLA 基因突变引起的,该基因编码一种称为 α-半乳糖苷酶 A(alpha-Gal A)的酶。这种酵素的缺乏会导致全身细胞内积聚一种特定类型的脂肪物质,称为神经酰胺三己糖基(Gb3 或 GL-3)。 Gb3 的积聚主要影响血管、肾臟、心臟和神经系统的细胞,导致多种症状和併发症。法布瑞氏症的症状通常出现在儿童期或青少年期,但症状出现的年龄及其严重程度在受影响的个体之间可能存在很大差异。法布瑞氏症的典型症状之一是神经性疼痛,这种疼痛可能很严重且是慢性的。这种疼痛通常影响手和脚等四肢,通常被描述为灼热或刺痛。例如,根据国家法布瑞氏症基金会(NFDF)的数据,美国每年将四月定为法布瑞氏症宣传月。宣传计划专注于教育公众、患者、护理人员和医疗保健专业人员。这些措施旨在提高对法布瑞氏症的理解、诊断和管理,最终促进整个研究期间的市场成长。

市场概况
预测期 2026-2030
2024 年市场规模 18.6 亿美元
2030 年市场规模 26.6 亿美元
2025-2030 年复合年增长率 6.30%
成长最快的领域 网路药局
最大的市场 北美洲

主要市场驱动因素

诊断方面的进展

主要市场挑战

患者数量有限

主要市场趋势

生物标誌物开发

目录

第 1 章:产品概述

第 2 章:研究方法

第 3 章:执行摘要

第 4 章:顾客之声

第 5 章:全球法布瑞氏症治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 透过药物(Agalsidase Beta、Migalastat 等)
    • 依治疗(酵素替代疗法 (ERT)、伴侣治疗、底物减少疗法 (SRT)、其他)
    • 依给药途径(口服、肠胃外、其他)
    • 按配销通路(医院药房、零售药房、网路药房)
    • 按地区
    • 按公司分类(2024)
  • 市场地图

第 6 章:亚太地区法布瑞氏症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 印度
    • 澳洲
    • 日本
    • 韩国

第 7 章:欧洲法布瑞氏症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章:北美法布瑞氏症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 墨西哥
    • 加拿大

第 9 章:南美洲法布瑞氏症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章:中东和非洲法布瑞氏症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 最新动态
  • 产品发布
  • 合併与收购

第 13 章:全球法布瑞氏症治疗市场:SWOT 分析

第 14 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章: 大环境分析

第 16 章:竞争格局

  • Sanofi (Genzyme Corporation)
  • Takeda Pharmaceutical Company Limited
  • Amicus Therapeutics, Inc
  • JCR Pharmaceuticals Co., Ltd.
  • Protalix BioTherapeutics Inc.
  • Chiesi Farmaceutici SpA
  • Freeline Therapeutics Holdings PLC
  • Yuhan Corporation
  • M6P Therapeutics
  • ISU Abxis Co Ltd

第 17 章:策略建议

第18章调查会社について・免责事项

简介目录
Product Code: 18737

Global Fabry Disease Treatment Market was valued at USD 1.86 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.30% through 2030. Fabry disease, also known as Anderson-Fabry disease, is a rare and inherited genetic disorder that belongs to a group of conditions known as lysosomal storage disorders. This disease is caused by mutations in the GLA gene, which encodes an enzyme called alpha-galactosidase A (alpha-Gal A). The deficiency of this enzyme results in the accumulation of a specific type of fatty substance, known as globotriaosylceramide (Gb3 or GL-3), within cells throughout the body. This buildup of Gb3 primarily affects the cells of blood vessels, kidneys, heart, and nervous system, leading to a wide range of symptoms and complications. Symptoms of Fabry disease often appear in childhood or adolescence, although the age of symptom onset and their severity can vary widely among affected individuals. One of the hallmark symptoms of Fabry disease is neuropathic pain, which can be severe and chronic. This pain typically affects the extremities, such as the hands and feet, and is often described as burning or tingling. For instance, according to the National Fabry Disease Foundation (NFDF) designates April as Fabry Disease Awareness Month each year in the United States. Awareness programs focus on educating the public, patients, caregivers, and healthcare professionals. These initiatives aim to improve the understanding, diagnosis, and management of Fabry disease, ultimately contributing to market growth throughout the study period.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.86 Billion
Market Size 2030USD 2.66 Billion
CAGR 2025-20306.30%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Key Market Drivers

Advancements in Diagnosis

Genetic testing has become a cornerstone in the diagnosis of Fabry disease. Advances in genetic sequencing technology have made it more accessible and cost-effective to identify specific mutations in the GLA gene, which is responsible for the disease. Genetic testing can confirm the presence of Fabry disease and provide information about the specific genetic mutations involved. In some regions, newborn screening programs have been implemented to identify Fabry disease in infants shortly after birth. This early detection allows for prompt intervention and treatment, potentially preventing or delaying the onset of symptoms and organ damage. Researchers have been investigating biomarkers associated with Fabry disease. Biomarkers are measurable substances in the body that can indicate the presence of a disease or its progression. Biomarker research can aid in early diagnosis and monitoring the effectiveness of treatment. Clinical diagnostic criteria for Fabry disease have been refined and standardized. Healthcare professionals now have clearer guidelines and criteria to assist in diagnosing disease based on clinical symptoms and genetic testing results. For instance, in December 2022, Bio Sidus SA sponsored a clinical trial to assess the efficacy and safety of AGA BETA BS in FD patients previously stabilized with Fabrazyme. Also, Fabry disease pipeline products continue to drive market growth. For example, in August 2021, the European Commission approved Amicus Therapeutics' Galafold for long-term treatment of Fabry disease in patients aged 12 and above with an amenable mutation.

Key Market Challenges

Limited Patient Population

The small patient population with Fabry disease results in a limited market size for pharmaceutical companies. This can make it less economically attractive for these companies to invest in research and development of treatments for disease. Developing and gaining regulatory approval for new treatments, including clinical trials and research, is costly. In the case of rare diseases like Fabry disease, the small number of potential patients can make it challenging to recoup these expenses. Due to the small market size, the revenue potential for treatments for Fabry disease may be limited compared to drugs for more common conditions. This can affect the profitability of drug development efforts. Limited patient populations can result in challenges related to patient access to treatments and affordability. Even if effective treatments exist, they may not be accessible to all patients due to cost or availability. The rarity of Fabry disease can lead to delayed diagnosis or misdiagnosis, as healthcare providers may not be familiar with the condition. This can result in patients not receiving appropriate treatment until the disease has progressed. Limited patient populations can also result in a scarcity of clinical data on the disease and its treatment. This can make it challenging for healthcare providers to make informed treatment decisions. Recognizing the challenges posed by rare diseases, some regulatory agencies provide incentives for orphan drug development. These incentives can include extended market exclusivity and reduced regulatory fees.

Key Market Trends

Biomarker Development

Biomarkers can aid in the early diagnosis of Fabry disease, allowing for timely intervention and treatment initiation. Early diagnosis is essential for preventing or delaying the onset of symptoms and organ damage. Biomarkers can be used to monitor disease progression and assess the effectiveness of treatment over time. This enables healthcare providers to tailor treatment plans to individual patients' needs. Certain biomarkers may be associated with the severity of Fabry disease. Identifying these biomarkers can help predict disease outcomes and guide treatment decisions. Biomarkers can help determine how well a patient is responding to treatment. If treatment is effective, biomarkers may show improvements in disease-related indicators. Biomarkers can serve as valuable endpoints in clinical trials of new Fabry disease treatments. They provide objective measures of treatment efficacy and safety. The development of biomarkers supports the concept of personalized medicine, where treatments are tailored to individual patients based on their biomarker profiles. This approach can optimize treatment outcomes. Biomarkers provide insights into the underlying molecular and genetic mechanisms of Fabry disease. This knowledge can inform drug development efforts, leading to more targeted and effective therapies. Biomarkers can be used to stratify Fabry disease patients into different subgroups based on disease characteristics. This stratification can guide treatment decisions and improve patient outcomes. Biomarkers can help reduce diagnostic delays by providing objective evidence of Fabry disease. This is particularly important because Fabry disease is often underdiagnosed or misdiagnosed.

Key Market Players

  • Sanofi (Genzyme Corporation)
  • Takeda Pharmaceutical Company Limited
  • Amicus Therapeutics, Inc
  • ISU ABXIS Co Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • Protalix BioTherapeutics Inc.
  • Chiesi Farmaceutici S.p.A.
  • Freeline Therapeutics Holdings PLC
  • Yuhan Corporation
  • M6P Therapeutics Inc.

Report Scope:

In this report, the Global Fabry Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fabry Disease Treatment Market, By Drugs:

  • Agalsidase Beta
  • Migalastat
  • others

Fabry Disease Treatment Market, By Treatment:

  • Enzyme Replacement Therapy (ERT)
  • Chaperone Treatment
  • Substrate Reduction Therapy (SRT)
  • Others

Fabry Disease Treatment Market, By Route of Administration:

  • Oral
  • Parenteral
  • Others

Fabry Disease Treatment Market, By Distribution Channel:

  • Hospital pharmacies
  • Retail pharmacies
  • Online Pharmacies

Fabry Disease Treatment Market, By region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fabry Disease Treatment Market.

Available Customizations:

Global Fabry Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Fabry Disease Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drugs (Agalsidase Beta, Migalastat, others)
    • 5.2.2. By Treatment (Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT), others)
    • 5.2.3. By Route of Administration (Oral, Parenteral, others)
    • 5.2.4. By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online Pharmacies)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Fabry Disease Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drugs
    • 6.2.2. By Treatment
    • 6.2.3. By Route of Administration
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Fabry Disease Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drugs
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. India Fabry Disease Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drugs
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Australia Fabry Disease Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drugs
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Distribution Channel
    • 6.3.4. Japan Fabry Disease Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Drugs
        • 6.3.4.2.2. By Treatment
        • 6.3.4.2.3. By Route of Administration
        • 6.3.4.2.4. By Distribution Channel
    • 6.3.5. South Korea Fabry Disease Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Drugs
        • 6.3.5.2.2. By Treatment
        • 6.3.5.2.3. By Route of Administration
        • 6.3.5.2.4. By Distribution Channel

7. Europe Fabry Disease Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drugs
    • 7.2.2. By Treatment
    • 7.2.3. By Route of Administration
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Fabry Disease Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drugs
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. Germany Fabry Disease Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drugs
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. Spain Fabry Disease Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drugs
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. Italy Fabry Disease Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drugs
        • 7.3.4.2.2. By Treatment
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. United Kingdom Fabry Disease Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drugs
        • 7.3.5.2.2. By Treatment
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Distribution Channel

8. North America Fabry Disease Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drugs
    • 8.2.2. By Treatment
    • 8.2.3. By Route of Administration
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Fabry Disease Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drugs
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. Mexico Fabry Disease Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drugs
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. Canada Fabry Disease Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drugs
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Distribution Channel

9. South America Fabry Disease Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drugs
    • 9.2.2. By Treatment
    • 9.2.3. By Route of Administration
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Fabry Disease Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drugs
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. Argentina Fabry Disease Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drugs
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. Colombia Fabry Disease Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drugs
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Fabry Disease Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drugs
    • 10.2.2. By Treatment
    • 10.2.3. By Route of Administration
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Fabry Disease Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drugs
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Saudi Arabia Fabry Disease Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drugs
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. UAE Fabry Disease Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drugs
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Fabry Disease Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Sanofi (Genzyme Corporation)
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Takeda Pharmaceutical Company Limited
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Amicus Therapeutics, Inc
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. JCR Pharmaceuticals Co., Ltd.
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Protalix BioTherapeutics Inc.
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. Chiesi Farmaceutici S.p.A.
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Freeline Therapeutics Holdings PLC
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Yuhan Corporation
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. M6P Therapeutics
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10.ISU Abxis Co Ltd
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer